Existing Molecules Find New Calling as Medical Countermeasures

Innovation is percolating around new approaches to treating injuries that result from chemical, biological, radiological and nuclear defense, as well as other public health emergencies. With funding from BARDA and other government entities, commercial pharmaceutical and biotechnology firms are seeking to repurpose existing molecules to save more lives.

Old Drug, New Tricks: Lovelace Paves Fresh Path for Approved Cancer Therapy

The established cancer drug topotecan may hold promise as a more targeted therapy for patients with small-cell lung cancer (SCLC), according to the results of a study presented by Lovelace Biomedical scientists. The findings are significant, as lung cancer remains one of the leading causes of cancer deaths worldwide. New treatment options are direly needed, […]

Animal Behavioral Management Is Core to Preclinical Success

For preclinical pharmacology and toxicology studies to succeed, it’s essential that investigators and their teams use best practices for animal enrichment and environmental enhancement. Animal stress — which can stem from lack of trust in the researchers or an inability to express natural, species-specific behaviors — can compromise study data.

The Less Cough, the Better: Lovelace Biomedical, Novartis Research Collaboration Aims to Improve Inhaled Drugs

Inhaled medicines play an essential role in treating respiratory conditions and many other diseases, from pulmonary fibrosis to asthma. However, a dose of inhaled medicine often results in a cough — an adverse reaction that can be both uncomfortable and counterproductive. It’s a reaction that drug developers seek to avoid as they develop the next […]

Lovelace Research Spotlight: Aerosol-Delivered Gene Therapy for Cystic Fibrosis

In a key study published in Human Gene Therapy Clinical Development, Lovelace Biomedical researchers found that delivering AAV gene therapy for cystic fibrosis by inhalation was both feasible and safe.

Nose-Only Inhalation of microRNA Shows Promise for Pulmonary Fibrosis

Lovelace Biomedical designed a nose-only inhalation exposure system to evaluate an investigational microRNA-based therapy for pulmonary fibrosis — and through its findings, has helped to further advance a novel approach to treating a long-underserved disease.